Moderna COVID-19 Vaccine Gets Positive Review From FDA Staff

Kerry Dooley Young

December 15, 2020

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center.

US regulators on Tuesday posted a largely positive review of Moderna Inc's SARS-CoV-2 vaccine, signaling that the nation might soon have a second shot available to prevent COVID-19.

The staff of the US Food and Drug Administration (FDA) released its briefing document ahead of Thursday's advisory committee meeting on Moderna's mRNA-1273 vaccine. The product is similar to the first COVID-19 vaccine cleared for use in the United States. Both the Moderna and rival Pfizer-BioNTech vaccines use a new approach — mRNA instructions — to spur the immune system into action.

The FDA on December 11 granted an emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine for people ages 16 and older, following a vote in its favor by an advisory committee. Both the Pfizer and Moderna vaccines are intended to be taken in a two-dose regimen.

Cambridge, Massachusetts-based Moderna is seeking an EUA for use of its vaccine in people ages 18 and older. In the briefing document, the FDA staff noted that study data indicates the primary efficacy endpoint demonstrated vaccine efficacy (VE) of 94.1% (95% CI, 89.3% - 96.8%), with 11 COVID-19 cases in the vaccine group and 185 COVID-19 cases in the placebo group.

The FDA staff review also notes that the data gathered so far suggests the Moderna vaccine works better in younger people and may protect against severe forms of COVID-19.

"The VE in this analysis when stratified by age group was 95.6% (95% CI, 90.6% - 97.9%) for participants 18 to younger than 65 years of age and 86.4% (95% CI, 61.4% - 95.5%) for participants 65 years of age and older," the FDA staff said in the review. "A final secondary efficacy analysis also supported efficacy against protocol-defined severe COVID-19, with 30 cases in the placebo group vs 0 cases in the vaccine group."

The FDA staff also said data from a November 11 interim analysis of about 30,350 study participants "supported a favorable safety profile, with no specific safety concerns identified that would preclude issuance of an EUA."

Bell Palsy Cases

There have been cases of Bell palsy seen in testing of both the Pfizer-BioNTech and Moderna vaccines, but neither product has been definitively linked to this risk. The handout prepared for clinicians for the Pfizer-BioNTech vaccine mentions that there were four cases of Bell palsy in people who received the active drug in testing, but none reported in the placebo group.

"Currently available information is insufficient to determine a causal relationship" with the Pfizer-BioNTech vaccine, the clinician handout says. "There were no other notable patterns or numerical imbalances between treatment groups for specific categories of non-serious adverse events (including other neurologic or neuroinflammatory, and thrombotic events) that would suggest a causal relationship to Pfizer-BioNTech COVID-19 vaccine."

As with the FDA briefing for the advisory committee meeting on the Pfizer-BioNTech vaccine, the agency staff made note of cases of Bell palsy seen during testing of the Moderna vaccine in the document posted Tuesday.

In the review of the Moderna vaccine, the FDA staff noted "a small imbalance in the number of participants reporting Bell's palsy (facial paralysis), with 3 vaccine recipients and 1 placebo recipient reporting this medically attended adverse event."

One case of Bell palsy in the vaccine group was considered a serious adverse event (SAE). A 67-year-old woman with diabetes was hospitalized for stroke because of new facial paralysis 32 days after vaccination. The FDA staff said the case has been reported as resolved.

Another Bell palsy case in the Moderna vaccine group occurred 28 days after vaccination in a 30-year-old woman who reported an upper respiratory infection 27 days before onset of her facial paralysis. This case has also been reported as resolved. Another Bell palsy case in the vaccine group involved a 72-year-old woman and was still ongoing at the time of a report included in Moderna's EUA application.

The Bell palsy case in the placebo group occurred 17 days after injection in a 52-year-old-man, the FDA staff said, and the case has resolved.

The FDA staff said that "causality assessment is confounded by predisposing factors" seen in study participants who developed Bell palsy. 

"However, considering the temporal association and biological plausibility, a potential contribution of the vaccine to the manifestations of these events of facial palsy cannot be ruled out," the agency staff said. "FDA will recommend surveillance for cases of Bell's palsy with deployment of the vaccine into larger populations."

The FDA staff's comment on the Moderna vaccine's safety profile was similar to their review comments for the Pfizer-BioNTech vaccine.

"[There] were no other notable patterns or numerical imbalances between treatment groups for specific categories of adverse events, including other neurologic, neuro-inflammatory, and thrombotic events, that would suggest a causal relationship to the Moderna COVID-19 vaccine," the FDA staff said.

Storage Ease

The Moderna vaccine "vials can be stored refrigerated between 2° to 8 °C (36° to 46 °F) for up to 30 days prior to first use. Unopened vials may be stored between 8° to 25 °C (46° to 77 °F) for up to 12 hours. After the first dose has been withdrawn, the vial should be held between 2° to 25°C (36° to 77 °F) and discarded after 6 hours," the FDA staff writes.

In contrast, the recently authorized Pfizer COVID-19 vaccine must be shipped and stored at -70 °C (-94 °F), significantly below the standard for most vaccines, including Moderna's, of 2° to 8 °C (36° to 46 °F).

For more news, follow Medscape on Facebook, Twitter, Instagram, and YouTube.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.